NCT00049790View on ClinicalTrials.gov

Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Study Completion Date

December 31, 2004

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

recombinant human Angiostatin protein

DRUG

paclitaxel

DRUG

carboplatin

Trial Locations (1)

46202

Indiana Cancer Pavilion, Indiana University, Indianapolis

Sponsors
All Listed Sponsors
lead

CASI Pharmaceuticals, Inc.

INDUSTRY

NCT00049790 - Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter